Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

Video

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses 2 new agents, regorafenib and TAS-102, for the treatment of patients with colorectal cancer.

Phase III studies have shown that both agents improved outcomes when compared with placebo in refractory settings, Bekaii-Saab explains.

Currently, there is only sequencing data for patients to receive regorafenib first followed by TAS-102; therefore, that is how the agents are used together. However, Bekaii-Saab emphasizes that there are certain instances where one therapy should be used versus the other.

<<<

View more from the 2016 School of Gastrointestinal Oncology

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Amin Nassar, MD
Haeseong Park, MD, MPH
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.